GlassScriptPhysician profile
Katherine T Baker
NPI 1962520411
$1,539.14
in general payments reported to CMS, 2019-2025
18 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $290 · 2022: $341 · 2023: $251 · 2024: $326 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $562.67 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $162.04 | 2022-2025 | |
| Lilly USA, LLC | $152.36 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $126.71 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.32 | 2021-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.68 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.21 | 2022 | |
| Astellas Pharma US INC | $47.59 | 2024 | Veozah |
| Esperion Therapeutics, INC. | $45.60 | 2021 | |
| Supernus Pharmaceuticals, INC. | $43.49 | 2022-2023 | Qelbree |
| Astrazeneca Pharmaceuticals LP | $36.07 | 2024 | Farxiga |
| Glaxosmithkline, LLC. | $32.34 | 2021-2023 | Bexsero |
| Merck Sharp & Dohme LLC | $30.28 | 2021-2022 | |
| Exact Sciences Corporation | $27.50 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $24.91 | 2024 | Repatha, Otezla |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $18.99 | 2021 | |
| Genentech USA, INC. | $16.86 | 2022 | |
| Amarin Pharma, INC. | $16.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.